Destiq

Desvenlafaxine

Major depressive disorder.

50 mg once daily. Max: 200 mg daily. Severe renal impairment (CrCl <30 mL/min) or ESRD 50 mg every other day.

May be taken with or without food: Swallow whole, do not divide/crush/chew/dissolve.

Hypersensitivity to desvenlafaxine succinate, venlafaxine HCl. Not to be used in combination w/ or w/in 14 days of discontinuing treatment w/ MAOI. Patients treated w/ reversible MAOI eg, linezolid or in whom IV methylene blue has been administered.

Monitor patients for clinical worsening, suicidality or unusual changes in behavior. History of mania/hypomania; serotonin-syndrome or NMS-like reactions; raised IOP or at risk of acute narrow-angle glaucoma; underlying conditions compromised by increased BP; CV, cerebrovascular, lipid metabolism or seizure disorders; hyponatremia. Control preexisting HTN prior to treatment. May cause symptoms of sexual dysfunction. Regularly monitor BP & measure serum lipids during treatment. Avoid abrupt discontinuation. Not to be used concomitantly w/ venlafaxine HCl or other desvenlafaxine succinate-containing drugs. Not recommended in concomitant use w/ serotonin precursors eg, tryptophan supplements. Concomitant use w/ other serotonergic drugs eg, SSRIs, SNRIs, amphetamines, triptans; drugs impairing serotonin metabolism eg, MAOIs; antipsychotics or other dopamine antagonists; NSAIDs, aspirin or other drugs affecting coagulation or bleeding. May affect ability to drive & use machines. Pregnancy & lactation. Increased risk of suicidal thinking & behavior in childn & adolescents. Ped patients <18 yr. Elderly.

Insomnia; headache, dizziness, somnolence; nausea, dry mouth, constipation. Decreased appetite; w/drawal syndrome, anxiety, nervousness, abnormal dreams, irritability, decreased libido, anorgasmia; tremor, paraesthesia, attention disturbance, dysgeusia; blurred vision, mydriasis; vertigo, tinnitus; tachycardia, palpitations; increased BP, hot flush; yawning; diarrhoea, vomiting; hyperhidrosis, rash; musculoskeletal stiffness; erectile dysfunction, delayed ejaculation; fatigue, asthenia, chills, feeling jittery; abnormal LFT, increased/decreased wt.

Serotonin syndrome w/ other agents affecting serotonergic neurotransmitter system eg, triptans, SSRIs, other SNRIs, amphetamines, lithium, sibutramine, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine or St. John's wort; drugs impairing serotonin eg, MAOIs including linezolid, methylene blue; serotonin precursors eg, tryptophan supplements. Increased exposure w/ potent CYP3A4 inhibitors. Increased conc of CYP2D6-metabolized drugs. CNS-active drugs, alcohol.

Antidepressants

N06AX23 - desvenlafaxine ; Belongs to the class of other antidepressants.

B